The results of staged endovascular revascularization with use of stents with third generations of drug-eluting and biodegradable polymer in patients with acute coronary syndrome and multivessel coronary artery disease

Cover Page

Cite item

Full Text

Abstract

Background. Acute coronary syndrome (ACS) is currently the leading cause of people’s death worldwide.

Objective. Based on the analysis of a combined end point, MACCE, to estimate the efficacy and safety of the strategy of staged endovascular revascularization in comparison with heart bypass surgery in patients with ACS and multivessel involvement in a distant time period.

Methods. We have performed an analysis of the long-term results of staged endovascular revascularization of the myocardium using 3d generation drug-eluting stents with a biodegradable polymer coating in patients with ACS and multivessel involvement, in comparison with the results of heart bypass surgery.

Results. According to the non-inferiority hypothesis test, the non-inferior efficacy of staged endovascular revascularization in comparison with heart bypass surgery has not been proven, using the MACCE combined point of emerging major cardiovascular events, the frequency of repeated revascularization in the groups does not exhibit statistically significant differences.

Conclusion. Heart bypass surgery is comparable to endovascular revascularization with the use of 3d generation drug-eluting stents in the frequency of repeated revascularizations.

About the authors

Aleksandr V. Bocharov

Kostroma regional clinical hospital named after Korolev E.I.

Author for correspondence.
Email: bocharovav@mail.ru
ORCID iD: 0000-0002-6027-2898
SPIN-code: 6073-1445
ResearcherId: C-6324-2019

Cand. Med. Sc., Chief of Department, Endovascular Surgeon

Russian Federation, 156013, Kostroma, pr. Mira 114

Leonid V. Popov

National Medical and Surgical Center named after N.I. Pirogov

Email: popovcardio@mail.ru
ORCID iD: 0000-0002-0530-3268

doctor of medical Sciences, Professor, head of the Department of cardiac surgery

Russian Federation, 105203, Moscow, Nizhnyaya Pervomayskaya str., 70

References

  1. Fact sheet. [Updated January 2017] The top 10 causes of death. Available from: http://www.whogis.com/mediacentre/factsheets/fs310/en/.
  2. Corcoran D, Grant P, Berry C. Risk stratification in not-ST elevation acute coronary syndromes: risk scores, biomarkers and clinical judgment. Int J Cardiol Heart Vasc. 2015;8:131–137. doi: 10.1016/j.ijcha.2015.06.009.
  3. Nicholl J, Mason S. Return of the «corridors of shame». BMJ. 2013;347:f4343. doi: 10.1136/bmj.f4343.
  4. O’Gara PT, Kushner FG, Ascheim DD, et al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2013;61(4):e78–e140. doi: 10.1016/j.jacc.2012.11.019.
  5. Neumann F, Sousa-Uva M, Ahlsson A, et al. 2018 ESC/EACTS Guidelines on myocardial revascularization. Eur Heart J. 2019;40(2):87–165. doi: 10.1093/eurheartj/ehy394.
  6. Roffi M, Patrono C, Collet JP, et al. 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: task force for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J. 2016;37(3):267–315. doi: 10.1093/eurheartj/ehv320.
  7. Ibanez B, James S, Agewall S, et al. 2017 ESC Guide-lines for the management of acute myocardial infaction in patients presenting with ST-segment elevation:the task force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J. 2018;39(2):119–177. doi: 10.1093/eurheartj/ehx393.
  8. Moreno R, Mehta SR. Nonculprit vessel intervention: let’s COMPLETE the evidence. Rev Esp Cardiol (Engl Ed). 2017;70(6):418–420. doi: 10.1016/j.rec.2016.12.029.
  9. Bangalore S, Toklu B, Wetterslev J. Complete versus culprit-only revascularization for ST-segment-elevation myocardial infarction and multivessel disease: a meta-analysis and trial sequential analysis of randomized trials. Circ Cardiovasc Interv. 2015;8(4). pii: e002142. doi: 10.1161/CIRCINTERVENTIONS.114.002142.
  10. Elgendy IY, Mahmoud AN, Kumbhani DJ, et al. Complete or culprit-only revascularization for patients with multivessel coronary artery disease uundergoing percutaneous coronary intervention: a pairwise and network meta-analysis off randomized trials. JACC Cardiovasc Interv. 2017;10(4):315–324. doi: 10.1016/j.jcin.2016.11.047.
  11. Thygesen K, Alpert JS, Jaffe AS, Simoons ML. Third universal definition of myocardial infarction. Eur Heart J. 2012;33(20):2551–2567. doi: 10.1093/eurheartj/ehs184.
  12. Gnavi R, Rusciani R,Dalmasso M, et al. Gender, socioeconomic position, revascularization procedures and mortality in patients presenting with STEMI and NSTEMI in the era of primary PCI. Difference sorinequties? Int J Cardiol. 2014;176(3):724–730. doi: 10.1016/j.ijcard.2014.07.107.
  13. U.S. Department of Health and Human Services;Food and Drug Administration; Center for Drug Evaluation and Research (CDER); Center for Biologics Evaluation and Research (CBER). Non-inferioty clinical trials to establish effectiveness. Guidance for industry. [November 2016] Available from: https://www.fda.gov/downloads/Drugs/Guidances/UCM202140.pdf.
  14. Serruys PW, Morice M-C, Kappetein P, et al. Percutaneous coronary intervention versus coronary-artery bypass grafting for severe coronary artery disease. N Engl J Med. 2009;360:961–972. doi: 10.1056/NEJMoa0804626.
  15. Kappetein AP. Optimal revascularization strategy with three-vessel disease and/or left main disease. The 2-year outcomes of the SYNTAX trial. [September 2, 2009] Presented at: ESC Congress 2009. Barcelona, Spain. Available from: https://docslide.net/download/link/optimal-revascularization-strategy-in-patients-with-three-vessel-disease-andor-left-main-disease-the-2-year-outcomes-of-the-syntax-trial-a-pieter-kappetein.
  16. Eefing F, NathoeH, Dijk D, et al. Randomized comparison between stenting and off-pump bypass surgery in patients referred for angioplasty.Circulation. 2003;108(23):2870–2876. doi: 10.1161/01.CIR.0000100723.50363.2C.
  17. Thiele H, Oettel S, Jacobs S, et al. Comparison of bare-metall stenting with minimally invasive bypass surgery for stenosis of the left anterior descending coronary artery: a 5-year follow-up. Circulation. 2005;112(22):3445–3450. doi: 10.1161/CIRCULATIONAHA.105.578492.
  18. Thuijs D, Mohr FW, Serruys PW, et al. 10-year survival after bypass surgery versus drug-eluting stents: preliminary results of the randomized SYNTAX extended survival study «SYNTAXES». 2018. Available from: https://www.acc.org/~/media/Clinical/PDF-Files/Approved-PDFs/2018/09/21/TCT-2018-Slides/Sept24-Mon/3pmET_SYNTAXES-tct-2018.pdf.
  19. Park SJ, Kim YH, Park DW, et al. Randomized trial of stents versus bypass surgery for left main coronary artery bypass surgery. N Engl J Med. 2011;364(18):1718–1727. doi: 10.1056/NEJMoa1100452.
  20. Ягафаров И.Р., Сибагатуллин Н.Г., Закиров И.Р., и др. Региональный опыт хирургического лечения острого коронарного синдрома // Казанский медицинский журнал. — 2015. — Т96. — №3. — С. 330–334. [Yagafarov IR, Sibagatullin NG, Zakirov IR, et al. Regional experience of acute coronary syndrome surgical treatment. Kazan Med J. 2015;96(3):330–334 in Russ] doi: 10.17750/KMJ2015-330.
  21. Boudriot E, Thiele H, Walther T, et al. Randomized comparison of percutaneous coronary intervention with sirolimus-eluting stents versus coronary artery bypass grafting in unprotected left main stem stenosis. J Am Coll Cardiol. 2011;57(5):538–545. doi: 10.1016/j.jacc.2010.09.038.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download
2. Fig. The results of statistical analysis of non-inferiority criteria for the frequency of MACCE events between the PCI and AKSH groups

Download (9KB)
Indexing metadata

Copyright (c) 2019 Bocharov A.V., Popov L.V.

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies